Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“The numbers are in – and WOW.
14,902 physicians joined virtually from China for a Live meeting from Chicago – for “Featuring Contents from ASCO 78: A400 Study Data Interpretation” during American Society of Clinical Oncology (ASCO) Annual meeting ASCO26 in Chicago!
Amazing discussing next-generation selective RET inhibitor Lunbotinib Phase 1 & 2 data with terrific colleagues meeting link below.”
Other articles featuring Vivek Subbiah on OncoDaily.